Direct comparison of btype natriuretic peptide bnp and aminoterminal probnp in a large population of patients with chronic and symptomatic heart failure. Design val heft was an international, randomized, multicenter, doubleblind trial that compared valsartan and placebo added to prescribed treatment in 5010 patients with chronic heart. Finally, valsartan was associated with only a moderate increase in ejection fraction when compared with other prior trials involving ace inhibitors and betablockers. The aim of this study was to determine echocardiographic predictors of outcome in patients with advanced heart failure hf due to severe left ventricular lv systolic dysfunction in the betablocker evaluation of survival trial best. Additional trials established this was a class effect for aceinhibitors. In a dosedependent fashion, hyd suppressed the production of the free radicals. Data from patients with hfref val heft valsartan heart failure trial and hfpef ipreserve irbesartan in heart failure with preserved ejection fraction study trials show that despite significantly higher baseline levels of np in hfref, the hazard for mortality associated with 1 log unit increase in nterminal probtype natriuretic.
In the resolvd and valheft studies, not all patients were treated with an acei, and only the subgroups that were are included in this metaanalysis. Thus, the results of the charmalternative study, along with subgroup analysis in the valheft trial of 7% of patients who were not on ace inhibitors, have shown that arbs specifically candesartan and valsartan confer significant benefit on mortality and morbidity in patients with hf who are intolerant of ace inhibitors and therefore. In hf patients not receiving aceis, valsartan reduced allcause mortality by 33 % and composite mortality and morbidity risk by 44 % compared with placebo in the val heft trial. Valheft was a randomized, placebocontrolled, doubleblind, parallelarm multicenter trial. The relative and combined ability of highsensitivity. Metaanalyses of mortality and morbidity effects of. Gdf15 increases during tissue injury and inflammatory states and is associated with cardiometabolic risk. Effects of valsartan on morbidity and mortality in. Conclusionsin this study, baseline sst2 was nonlinearly associated with patient outcomes but did not provide substantial. Natera announced results of a prospective validation study published in the journal of clinical medicine demonstrating 100% accuracy of its panorama noninvasive prenatal test in determining zygosity, fetal sex, and chromosomal abnormalities in twins as early as 9 weeks of gestation. Digoxin in heart failure with a reduced ejection fraction.
A randomized trial of the angiotensinreceptor blocker valsartan. Oct 25, 2018 similarly, in the valheft study, change in st2 values over time was significantly and independently associated with mortality. An echocardiographic substudy of valheft reported a modest reversal of lv remodeling in patients treated with valsartan, with an average reduction in the enddiastolic diameter of 0. Pdf previous trials metoprolol crxl randomised intervention trial in. Angiotensin receptor blockers for chronic heart failure and. Study design the valsartan heart failure trial valheft was a randomized, placebocontrolled, doubleblind, parallelgroup trial. Valheft was a randomized, doubleblind parallelarm study in which hf patients new york heart association class iiiv received either valsartan n 2511, forcetitrated to 160 mg twice daily or placebo n 2499 in addition to prescribed hf.
Effect of valsartan added to background ace inhibitor. Design valheft was an international, randomized, multicenter, doubleblind trial that compared valsartan and placebo added to prescribed treatment in. Similarly, in the valheft study, change in st2 values over time was significantly and independently associated with mortality. The sudden cardiac death in heart failure trial scd heft was designed to evaluate the hypothesis that amiodarone or a conservatively programmed shockonly, singlelead implantable cardioverter defibrillator icd would decrease the risk of death from any cause in a broad population of patients with mildtomoderate heart failure. Patient information for cuenca 80mg filmcoated tablets including dosage instructions and possible side effects. Dec 14, 2004 the demographic and baseline characteristics of this subgroup were similar to the overall val. The value study also showed that the treatment with valsartan significantly inhibited the new. Valsartan treatment lowered plasma crp concentrations in the valsartan heart failure trial valheft.
Angiotensin ii contributes to cardiac remodeling that leads to decreased left ventricular function and progressive heart failure. The valsartan heart failure trial valheft was a randomized, placebocontrolled, doubleblind, parallelgroup trial. Over 10 million scientific documents at your fingertips. The key features of the design of valheft trial are shown in tables 1 and 2. The role of angiotensin receptor blockers in reducing the. Aims of the present study were 1 to confirm the prognostic role of anemia in patients with heart failure hf and 2 to analyze this aspect in relatively unselected patients with hf monitored prospectively in a community setting inchf, and in patients selected for enrolment into the valsartan heart failure trial valheft. Angiotensin receptor blockers for chronic heart failure. The valsartan heart failure trial val heft was a randomized, placebocontrolled, doubleblind, parallelgroup trial.
Valsartan benefits left ventricular structure and function in heart failure. Smith r, fletcher r, for the vheft va cooperative studies. In summary, this trial demonstrated that treating patients with congestive heart failure with. Valheft, which included serial echocardiograms in all patients randomized, confirmed the relationship between attenuation or reversal of remodeling and clinical benefit. Direct comparison of btype natriuretic peptide bnp and. The africanamerican heart failure trial aheft was a randomized, placebocontrolled, doubleblind trial with patients recruited at 161 centers in the united states. The valheft study supports the use of valsartan in patients with chronic hf who are intolerant to ace inhibitors. The 2001 valsartan heart failure trial valheft provided an interesting window to the role of arb therapy in hfref. It is highly expressed in cardiomyocytes, adipocytes, macrophages, endothelial cells, and vascular smooth muscle cells in normal and pathological condition. The study was designed with two primary end points. The vasodilatorheart failure trial i vheft i sought to explore the effects of using a combination of hydralazine and isosorbide dinitrate in managing heart failure. As the studies of vasodilator therapies in heart failure developed, there. The valsartan heart failure trial valheft was a randomized.
The valsartan heart failure trial valheft was a randomized, place. Although the study populations were similar in most respects, differences were noted with regard to the number of patients treated with an ace inhibitor elite ii 23% prior to randomisation, val heft 92% and with a betablocker elite ii 22%, val heft 33%. Specifically, the v heft ii trial demonstrated that enalapril was superior to isdnhydralazine in patients with mildtomoderate heart failure. Sep 19, 2001 although the study populations were similar in most respects, differences were noted with regard to the number of patients treated with an ace inhibitor elite ii 23% prior to randomisation, valheft 92% and with a betablocker elite ii 22%, valheft 33%. Patients at 302 centers in 16 countries gave written informed. Severity of left ventricular remodeling defines outcomes. Study design and patient selection valheft was a randomized, placebocontrolled, doubleblind trial that enrolled 5010 patients with new york heart association functional class ii to iv hf and an ef of val heft, journal of cardiac failure on deepdyve, the largest online rental service for scholarly research with thousands of academic publications available at your fingertips. A posthoc subgroup analysis found increased mortality in individuals on valsartan, ace inhibitor therapy, and beta blockers. The 1992 solvd treatment study established enalapril as first line therapy in preventing hf progression. In total, 300 sites from 16 countries participated in the valheft trial. The demographic and baseline characteristics of this subgroup were similar to the overall val.
Lead investigator of the trial, dr salim yusuf mcmaster university, hamilton, on, commented. The key features of the design of val heft trial are shown in tables 1 and 2. Effect of carvedilol on outcome after myocardial infarction. Mean doses of acei at randomisation, during and at the conclusion of the study are listed in table 2. Effects of valsartan on circulating brain natriuretic. Arbs or angiontension ii receptor blockers, were evaluated as substitutes for acei in the 2001 valsartan heart failure trial or valheft. Cardiac biomarkers and heart failure american college of. Additional studies are needed, however, to fully define the role of angiotensin ii receptor antagonists in the management of this very. Future studies of betablockade may focus on these patients or patients. Sudden cardiac death in heart failure trial scdheft. Simultaneously published, the v heft ii and solvd trials were landmark studies that were the first to demonstrate mortality benefit with ace inhibition in patients with mildtomoderate heart failure. Combination of isosorbide dinitrate and hydralazine in blacks. A direction of change in ntprobnp values over time closely reflected changes in prognosis. Objective current methods of risk stratification in patients with type 2 diabetes are suboptimal.
In both elite ii and val heft, patients were stratified according to background beta. Although the study populations were similar in most respects, differences were noted with regard to the number of patients treated with an ace inhibitor elite ii 23% prior to randomisation, valheft 92% and with a betablocker elite ii 22%, valheft 33%. Among other things, it offers the ability to assess chamber size, shape, and function, filling pressures, pulmonary artery pressure, valvular disease, congenital abnormalities, and. A total of 5,010 patients with stable, symptomatic hf who were on prescribed hf therapy and had left ventricular ejection fraction lvef ii. The explanation for these discrepancies is not clear. Pdf the carvedilol prospective randomized cumulative survival. To compare the efficacy of the ace inhibitor enalapril with that of hydralazine plus isosorbide dinitrate in patients with chronic. Effect of valsartan added to background ace inhibitor therapy. Our metaanalysis provides some insights into the controversy surrounding the effect of dual ras blockade in the treatment of patients with hf. Valheft was a randomized, doubleblind parallelarm study in which hf patients new york heart association class iiiv received either valsartan n 2511, forcetitrated to 160 mg twice daily. Valheft was a randomized, doubleblind parallelarm study in which hf patients new york heart association class iiiv received either valsartan n 2511, forcetitrated to 160 mg twice daily or placebo n 2499 in addition to prescribed hf therapy. There was little change in mean dose of acei over the duration of the val. According to the american college of cardiologyamerican heart association practice guidelines, echocardiography is the single most useful test in the evaluation of patients with heart failure hf. Severity of left ventricular remodeling defines outcomes and.
In the valheft study the prognostic values of bnp and ntprobnp were compared in patients with stable chronic hf and in that study ntprobnp was better in terms of predicting outcome. The 2001 valsartan heart failure trial val heft provided an interesting window to the role of arb therapy in hfref. Publications home of jama and the specialty journals of the. A total of 5,010 patients with stable, symptomatic hf who were on prescribed hf therapy and had left ventricular ejection fraction lvef 40% and left ventricular diameter in diastole. The vheft i study enrolled 642 men, of which 180 or 28% were african american.
Study design and patient selection valheft was a randomized, placebocontrolled, doubleblind trial that enrolled 5010 patients with new york heart association functional class ii to iv hf and an ef of val heft, journal of cardiac failure on deepdyve, the largest online rental service for scholarly research with thousands of academic publications available at. In this study of stable outpatients with systolic hf, good adherence to the home exercise training intervention over a median of 30 months occurred in only. A second large trial, val heft, was presented at the scientific sessions of the american heart association in 2000. The val heft study was a randomized, placebocontrolled, doubleblind, parallelarm multicenter trial. Publications home of jama and the specialty journals of. Baseline demographics of the valsartan heart failure trial cohn. In patients treated longterm after an acute myocardial infarction complicated by leftventricular systolic dysfunction, carvedilol reduced the frequency of allcause and cardiovascular mortality, and recurrent, nonfatal myocardial infarctions.
The sudden cardiac death in heart failure trial scdheft was designed to evaluate the hypothesis that amiodarone or a conservatively programmed shockonly, singlelead implantable cardioverter defibrillator icd would decrease the risk of death from any cause in a broad population of patients with mildtomoderate heart failure. However, among those patients who received ace inhibitors and. In the original valheft study, a total of 5,010 symptomatic hf patients were enrolled, 3,374 67% of whom were on digoxin at baseline. However, predicting outcome after hospital discharge for worsening hf may be more difficult, but is clinically relevant. Effect of valsartan on hospitalization in valheft request pdf. A preliminary report also revealed that changes in ef over time were associated with corresponding changes in mortality and morbidity risks. A subgroup analysis of the valsartan heart failure trial val heft was performed to evaluate the effects of the angiotensin ii receptor blocker, valsartan, in the patients with chronic heart. In both elite ii and valheft, patients were stratified according to background beta. In this viewpoint, milton packer and colleagues argue that reliance on a threshold of lvef. Serge masson, roberto latini, inder s anand, tarcisio vago, laura angelici, simona barlera, emil d missov, aldo clerico, gianni tognoni, jay n cohn, direct comparison of btype natriuretic peptide bnp and aminoterminal probnp in a large population of patients with chronic and symptomatic heart failure. Objectives the guideit guiding evidence based therapy using biomarker intensified treatment in heart failure study is designed to determine the safety, efficacy, and costeffectiveness of a strategy of adjusting therapy with the goal of achieving and maintaining a target nterminal probtype natriuretic peptide ntprobnp level of study of stable outpatients with systolic hf, good adherence to the home exercise training intervention over a median of 30 months occurred in only. Validation study definition of validation study by. Diabetes and heart failure the two diseases entities are highly coprevalent diabetes contributes to disease progression in hf and is associated with substantially worse prognosis, even when.
In summary, the valheft trial demonstrated an important role for arbs in the management of heart failure. Vasodilatorheart failure trial 1 vheft ii vasodilatorheart failure trial. Val heft enrolled 5010 patients, mainly new york heart association nyha functional class ii and iii with low ejection fraction and evidence of left ventricular dilatation. Heart failure with improved ejection fraction aha journals. Effects of valsartan on circulating brain natriuretic peptide. In the overall study population, valsartan caused significant improvements in new york heart association nyha class, ejection fraction, and hf signs and symptoms and. The current study assesses the ability of nterminal probtype natriuretic peptide ntprobnp and highsensitivity cardiac troponin t hsctnt to improve the prediction of cardiovascular events and death in patients with type 2 diabetes. In the valsartan heart failure trial valheft study, 14 a fourmonth logtransformed continuous ntprobnp value added incremental prognostic value to a baseline measurement in a multivariable model to predict mortality hr 1.
Effects of dual blockade in heart failure and renal. Growth differentiation factor15 gdf15 is a stress responsive cytokine. In a post hoc analysis of the combined end point and mortality in subgroups defined according to baseline treatment with. The trial randomized 5,010 with lvef 90% of the patients were on aceinhibitors but only 25% were on metoprolol or carvedilol. Combination of isosorbide dinitrate and hydralazine in. Val heft was a randomized, placebocontrolled, doubleblind, parallelarm multicenter trial. A randomized trial of the angiotensinreceptor blocker.
In summary, the val heft trial demonstrated an important role for arbs in the management of heart failure. These beneficial effects are additional to those of evidencebased treatments for acute myocardial infarction including ace inhibitors. Patients with stable, symptomatic hf n5010 who were on prescribed hf therapy and had lv ejection fraction 2. Angiotensin receptor blockers the cardiology advisor. Isosorbide dinitratehydralazine combination therapy in african. A comparison of the prognostic value of bnp versus nt. The vasodilatorheart failure trial i v heft i sought to explore the effects of using a combination of hydralazine and isosorbide dinitrate in managing heart failure. While the valheft study found that combination therapy was beneficial, 16 the astronaut 17 and atmosphere 26 studies did not. Study design and patient selection val heft was a randomized, placebocontrolled, doubleblind trial that enrolled 5010 patients with new york heart association functional class ii to iv hf and an ef of val heft end points5. The valheft study was a randomized, placebocontrolled, doubleblind, parallelarm multicenter trial. The valsartan heart failure valheft data, clinical chemistry, volume 52, issue 8, 1. Preventing readmission after hospitalization for acute.
451 510 1025 640 261 1201 1415 890 1121 24 567 1212 1333 878 619 1006 320 1494 603 1481 1555 635 953 1340 131 901 419 238 1217 587